TOP - February 2016, Vol 9, No 1
Patrick J. Medina, PharmD, BCOP
Professor of Clinical and Administrative Sciences
University of Oklahoma College of Pharmacy
Tulsa, OK
Steve Stricker, PharmD, MS, BCOP

In the February issue of The Oncology Pharmacist, we feature a recent study that was presented at the 2015 Palliative Care in Oncology Symposium on aprepitant (Emend), a centrally acting neurokinin-1 antagonist indicated for patients with chemotherapy-induced nausea and vomiting. The study authors found that aprepitant led to a reduction in cough frequency and improvement in the objective and subjective measures of cough in patients with lung cancer. We also highlight notable studies that were presented at the 57th American Society of Hematology Annual Meeting & Exposition, the American Society for Radiation Oncology 2015 Annual Meeting, and the San Antonio Breast Cancer Symposium.

In addition to conference news, we provide valuable insight on how the Affordable Care Act may affect drug pricing, US Food and Drug Administration news updates, using life insurance as a charitable vehicle, and treating patients with myelofibrosis.

In this issue's reader poll, we ask you whether certain treatments are beneficial for postmenopausal women with ductal carcinoma in situ. Please visit our website, www.TheOncologyPharmacist.com, and let us know whether this is what you have observed in your everyday practice. You can also send comments to info@TheOncologyPharmacist.com. We hope you will enjoy this issue, and look forward to your feedback.

Last modified: March 31, 2016